ESSA Pharma Inc. (NASDAQ:EPIX) COO Peter Virsik Sells 2,082 Shares

ESSA Pharma Inc. (NASDAQ:EPIX) (TSE:EPI) COO Peter Virsik sold 2,082 shares of the business’s stock in a transaction on Tuesday, September 3rd. The stock was sold at an average price of $6.03, for a total transaction of $12,554.46. Following the completion of the transaction, the chief operating officer now owns 9,164 shares of the company’s stock, valued at approximately $55,258.92. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

ESSA Pharma Stock Performance

Shares of ESSA Pharma stock opened at $5.93 on Wednesday. The business has a 50-day simple moving average of $5.12 and a 200-day simple moving average of $6.49. ESSA Pharma Inc. has a one year low of $2.58 and a one year high of $11.67. The company has a market cap of $263.07 million, a PE ratio of -9.41 and a beta of 1.82.

ESSA Pharma (NASDAQ:EPIX) (TSE:EPI) last issued its quarterly earnings results on Monday, August 5th. The company reported ($0.16) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.26) by $0.10. On average, sell-side analysts predict that ESSA Pharma Inc. will post -0.71 earnings per share for the current fiscal year.

Institutional Investors Weigh In On ESSA Pharma

Institutional investors have recently modified their holdings of the company. RTW Investments LP purchased a new position in ESSA Pharma in the fourth quarter valued at $15,171,000. Janus Henderson Group PLC lifted its holdings in ESSA Pharma by 7.9% during the 1st quarter. Janus Henderson Group PLC now owns 1,175,242 shares of the company’s stock worth $9,978,000 after buying an additional 85,760 shares during the last quarter. BNP Paribas Financial Markets boosted its position in shares of ESSA Pharma by 164.9% during the 4th quarter. BNP Paribas Financial Markets now owns 57,466 shares of the company’s stock worth $379,000 after acquiring an additional 35,771 shares in the last quarter. Finally, EntryPoint Capital LLC purchased a new position in shares of ESSA Pharma in the 1st quarter valued at about $38,000. 75.12% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Separately, Oppenheimer reiterated an “outperform” rating and issued a $17.00 target price on shares of ESSA Pharma in a report on Thursday, May 16th.

About ESSA Pharma

ESSA Pharma Inc, a clinical stage pharmaceutical company, focuses the development of small molecule drugs for the treatment of prostate cancer. The company's lead candidate EPI-7386, an androgen receptor based resistance mechanisms that develop in patients with castration-resistant prostate cancer and metastatic castration-resistant prostate cancer.